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required due to poor glycaemic control. Two alternative insulin
regimens were described for each scenario: injectable-only or
inhaled insulin to replace or reduce the number of daily injec-
tions. Only the characteristics of treatment varied; equal efﬁcacy
was assumed. Computer-assisted personal interviews were con-
ducted at six UK locations with people with diabetes aged over
18 years. After demonstration of the inhalation and pen injec-
tion devices, 344 respondents (66% male), 132 (mean age 49
years) with T1D and 212 (mean age 63 years) with T2D, rated
scenarios by time trade-off (TTO) and EQ-5D. RESULTS: A
majority of respondents preferred inhalation variants; the pro-
portions ranging from 63% to 81% across the scenarios, with
generally less than 10% indifferent between variants. Mean dif-
ferences between variants in TTO scores were 0.074, 0.076,
0.088, 0.053 and 0.043 for the 5 scenarios respectively (p <
0.005 for all comparisons). Mean EQ-5D differences between
variants were 0.043, 0.029, 0.037, 0.020, 0.021 for the 5 sce-
narios respectively (p < 0.05 for scenarios 1 and 3), driven mainly
by differences in pain/discomfort. Mean self-rated health was
similar between T1D and T2D respondents, at 0.83 (TTO) and
0.75 (EQ-5D). CONCLUSIONS: Inhaled insulin may offer 
the prospect for improved patient satisfaction when a patient’s
injectable insulin regimen requires adjustment. TTO was more
sensitive than EQ-5D to differences between scenarios and dif-
ferences between treatment variants within scenarios.
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OBJECTIVES: To analyse the effectiveness, costs and side-effects
of atypical versus typical antipsychotics for schizophrenia in
routine care. METHODS: A retrospective cohort study using
routine data from a statutory sickness fund in Germany with 5.4
million insured. Patients discharged from hospital with an ICD-
10 diagnosis of schizophrenia in 2003 were followed for 12
months. Rehospitalisation rates, mean hospital days, time to ﬁrst
hospital readmission, cost of inpatient and pharmaceutical care
and prescriptions to treat side-effects during follow-up were
analysed. To control for confounding, a severity index was con-
structed using data on prior hospitalisations due to schizophre-
nia in 2000, 2001 and 2002. RESULTS: A total of 3121 patients
were included into the study. There were no statistically signiﬁ-
cant differences in the effectiveness of atypical versus typical
antipsychotics on rehospitalisation during follow-up (rehospital-
isation rate ratio 1.07, 95% CI 0.86 to 1.33). Patients treated
with atypical antipsychotics received signiﬁcantly less medication
to treat extrapyramidal symptoms than those receiving typical
drugs (relative risk 0.26, 95% CI 0.18 to 0.38). There were con-
sistent but statistically non-signiﬁcant observations of atypical
drugs being more effective for severe cases (>61 prior hospital
days per year), whereas for new cases (no prior hospitalisation
in 2000–2002) and those in the mild and moderate severity strata
(0–14 and 14–61 prior hospital days per year) typical antipsy-
chotics seemed more effective in reducing various rehospitalisa-
tion outcomes. Costs were largely driven by inpatient care.
CONCLUSIONS: The effectiveness of atypical antipsychotics
for schizophrenia on rehospitalisation measures appeared similar
to typical drugs, whereas atypical antipsychotics clearly had a
favourable side-effect proﬁle with less medication against
extrapyramidal symptoms prescribed. Atypical antipsychotics
might be more effective for severe cases, typical drugs for new,
mild and moderate cases. With the exception of severe cases, the
higher costs for atypical antipsychotics were not offset by savings
from reduced inpatient care.
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OBJECTIVES: To proﬁle trends in the levels of treatment per-
sistence over time across several typical and atypical antipsy-
chotic agents among patients with schizophrenia in the Veterans
Health Administration (VA). METHODS: Using VA ﬁscal years
2000–2004, we deﬁned initiation of the target agent as 6-month
“clean” period of no target drugs prior to initiation and reserved
one year following the initiation to calculate treatment persis-
tence, or time to discontinuation, as deﬁned by a gap of >15 days
(a sensitivity analysis was also conducted using a gap of >30
days). Using a ﬂoating data approach, we created four time
periods for which analyses were conducted for each period. We
calculated hazard ratio using Cox proportional method and used
a multi-stage regression model, in which one set of covariates
was introduced into the model sequentially. RESULTS: Com-
pared to patients who initiated typical antipsychotics, those who
initiated atypical antipsychotics tended to have better treatment
persistence as reﬂected in longer stay on the medication within
one year between initiation and the ﬁrst gap of >15 or >30 days
(99 vs. 141 days on average; p < 0.001). However, between
October 1, 1999 and March 31, 2005, treatment persistence
with typical antipsychotics remained the same, whereas treat-
ment persistence with atypical antipsychotics decreased from
149 to 135 days. Among individual typical antipsychotics, treat-
ment persistence with chlorpromazine decreased from 110 to102
days, treatment persistence with haloperidol remained the same,
whereas treatment persistence with perphenazine increased from
116 to 128 days. CONCLUSION: Despite being efﬁcacious in
reducing symptoms of schizophrenia, the likelihood of sustain-
ing control of schizophrenia may depend on treatment persis-
tence. However, poor treatment persistence with antipsychotics
is a common problem among patients with schizophrenia. Future
research needs to explore factors associated with different levels
of treatment persistence across different antipsychotics.
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OBJECTIVE: To determine predictors of Global Assessment of
Functioning (GAF) score changes in Australian subjects with
schizophrenia treated with risperidone long-acting injection
(RLAI). METHODS: e-STAR (electronic-Schizophrenia Treat-
ment Adherence Registry) is an ongoing international observa-
